The ketamine problem in England, Wales, and Northern Ireland has morphed into something nobody anticipated. Deaths involving the drug have jumped twentyfold since 2014, but here is the twist: ketamine is rarely killing people on its own anymore. Instead, it has become a supporting player in increasingly dangerous cocktails of substances, often consumed by older, poorer users far removed from the dance floors where ketamine first made its recreational debut.
Between 1999 and 2024, coroners documented 696 deaths where illicit ketamine showed up in post-mortem testing. The numbers tell a stark story. In 2014, 15 people died with ketamine in their system. By 2024, researchers project that number will hit 197. Yet the proportion of deaths where ketamine actually caused the fatality has fallen from 60% in 2014 to just 43% in 2024.
The Polydrug Problem
What changed? The drug-use landscape shifted beneath everyone’s feet. The median number of substances found in ketamine-related deaths climbed from three in the early 2000s to six by 2020. Cocaine, heroin, benzodiazepines, and increasingly gabapentinoids now feature alongside ketamine in toxicology reports. People are mixing ketamine with sedatives like opioids and benzodiazepines, creating unpredictable effects that make it difficult to gauge dosing. The result is accidental overdoses where blame gets spread across multiple substances.
Dr. Caroline Copeland, who led the analysis at King’s College London, put it plainly:
We are seeing more ketamine-related deaths, but these deaths rarely involve ketamine alone. They are increasingly part of complex polydrug use patterns, often among people facing social disadvantage and entrenched drug dependence. This means single-drug policies, such as reclassification, are unlikely to tackle the real drivers of harm.
The findings come at a politically charged moment. U.K. officials are debating whether to reclassify ketamine from Class B to Class A under the Misuse of Drugs Act, the same category as heroin and cocaine. But the data suggests that legislative reclassification might miss the mark entirely. When deaths involve six different substances, cracking down on one seems almost quaint.
Ketamine’s appeal has broadened in part because it is cheap. A gram costs around 15 to 30 pounds, compared to 80 pounds for cocaine. An estimated 299,000 people in England and Wales reported using illicit ketamine in 2024, the highest number on record. Wastewater analysis backs this up, showing an 85% jump in ketamine consumption between 2023 and 2024. Organized crime groups have exploited legal supply chains, setting up front companies to import ketamine from India, Pakistan, and China under the guise of medical use, then diverting it to street markets.
From Ravers to Rough Sleepers
The demographic profile of ketamine deaths has shifted noticeably. The average age of death rose from 31.5 years between 1999 and 2019 to 33.7 years in the 2020-2024 period. More tellingly, the proportion of victims who were employed dropped from 54% to 42%. Meanwhile, the share living in the most deprived areas climbed from 26% to 34%. Recreational use in clubs and festivals, which once dominated the narrative, now accounts for just 29% of deaths where context was recorded, down from 75% in the early 2000s.
Ketamine has infiltrated the world of dependent drug use, where it serves functional purposes beyond getting high. Some users reportedly self-medicate with ketamine to dull the pain caused by ketamine-induced bladder damage, creating a destructive feedback loop. The drug also shows up alongside opioids and benzodiazepines in the harm-coping strategies of marginalized populations dealing with housing instability, unemployment, and chronic pain.
Men accounted for 85% of ketamine deaths between 2020 and 2024. Coroners ruled 89% of cases accidental, with just 6% determined to be suicides. Employment status varied, but 42% were unemployed at the time of death. Most victims were white and living with others rather than alone, though a growing fraction had no fixed address or resided in hostels.
The researchers stopped short of endorsing ketamine reclassification. Instead, they called for harm reduction measures like expanded drug-checking services, overdose prevention centers, and better integration of ketamine users into treatment programs. They also urged targeted education about polydrug risks and attention to structural issues like poverty and housing instability.
Copeland emphasized the need for a reality check in policy circles:
Illicit ketamine use has moved beyond the recreational setting. To reduce deaths, we need harm reduction, treatment, and social support strategies that reflect the realities of polydrug use, not just legislative changes focused on one substance.
Ketamine retains legitimate medical uses as an anesthetic and analgesic, with its S-enantiomer form approved for treatment-resistant depression in some countries. But the illicit version circulating in the U.K. exists in a different universe, one where purity is uncertain and combinations are often lethal. The rise of substances like “pink cocaine” or “Tuci,” which blends ketamine with MDMA, illustrates how users increasingly seek out polydrug experiences by design.
The National Programme on Substance Use Mortality, which compiled the data, relies on voluntary reports from coroners. That means the true death toll is likely higher than reported. Toxicology screening has also improved over time, catching more substances than in earlier years, which complicates direct comparisons. Still, the trends are unmistakable.
Whether ketamine gets bumped to Class A remains to be seen. What seems clear is that the drug’s role in U.K. mortality has less to do with ketamine itself and more to do with the chaotic landscape of substance use it now inhabits. Fixing that requires more than tougher penalties. It requires acknowledging that people mix drugs for reasons that go beyond recreation, in contexts shaped by desperation as much as desire.
Journal of Psychopharmacology: 10.1177/02698811251373058
ScienceBlog.com has no paywalls, no sponsored content, and no agenda beyond getting the science right. Every story here is written to inform, not to impress an advertiser or push a point of view.
Good science journalism takes time — reading the papers, checking the claims, finding researchers who can put findings in context. We do that work because we think it matters.
If you find this site useful, consider supporting it with a donation. Even a few dollars a month helps keep the coverage independent and free for everyone.